Telithromycin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Community Acquired Pneumonia (CAP)
Conditions
Community Acquired Pneumonia (CAP), Acute Exacerbation of Chronic Bronchitis (AECB)
Trial Timeline
May 1, 2004 → Dec 1, 2004
NCT ID
NCT00546676About Telithromycin
Telithromycin is a approved stage product being developed by Sanofi for Community Acquired Pneumonia (CAP). The current trial status is completed. This product is registered under clinical trial identifier NCT00546676. Target conditions include Community Acquired Pneumonia (CAP), Acute Exacerbation of Chronic Bronchitis (AECB).
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00288223 | Approved | Terminated |
| NCT00261105 | Approved | Completed |
| NCT00174694 | Approved | Completed |
| NCT00546676 | Approved | Completed |
| NCT00132938 | Approved | Completed |
| NCT00538018 | Approved | Completed |
| NCT00273520 | Phase 3 | Completed |
| NCT00537563 | Phase 3 | Completed |
| NCT00538148 | Approved | Completed |
Competing Products
17 competing products in Community Acquired Pneumonia (CAP)